A 58-year-old woman with chronic renal failure (eGFR 18 mL/min/1.73m²) is undergoing elective hip arthroplasty. She receives thiopental for induction and rocuronium 0.6 mg/kg IV for neuromuscular blockade. Intraoperatively, the train-of-four monitoring shows 1 out of 4 twitches at 30 minutes post-administration. At the end of the 2-hour surgery, train-of-four shows 0 out of 4 twitches. The surgeon requests muscle relaxation to be maintained. What is the most appropriate next step?

Explanation

## Rocuronium Management in Renal Failure **Key Point:** In patients with severe renal impairment, rocuronium (a non-depolarising, steroidal neuromuscular blocker) undergoes prolonged elimination, and repeated dosing risks profound, prolonged blockade. The appropriate strategy is to maintain the existing blockade and allow spontaneous recovery. ### Rocuronium Pharmacokinetics in Renal Disease | Parameter | Normal Kidney | Renal Failure (eGFR <30) | |-----------|---------------|-------------------------| | **Elimination Route** | Hepatic (70%), Renal (30%) | Hepatic only (renal clearance lost) | | **Duration of Action** | 30–40 minutes | 60–90+ minutes | | **Onset** | 60–90 seconds | 60–90 seconds (unchanged) | | **Accumulation Risk** | Low with single dose | HIGH with repeat dosing | | **Recovery Profile** | Predictable | Unpredictable, prolonged | **High-Yield:** Rocuronium is **hepatically metabolized via ester hydrolysis and organ-independent elimination** (Hofmann elimination and ester hydrolysis). However, 30% of normal elimination is renal, so in severe renal failure, the drug accumulates significantly with repeat dosing. ### Why Each Option Is Correct or Incorrect **Correct Approach (Option 1 — Wait for Spontaneous Recovery):** - The patient already has profound blockade (0/4 twitches) at 2 hours - Administering another dose would cause unpredictable, potentially irreversible paralysis - Spontaneous recovery will occur, albeit slowly, as hepatic metabolism continues - Monitoring with train-of-four ensures safety and guides reversal timing **Clinical Pearl:** In renal failure patients receiving rocuronium, the goal is **single-dose strategy**: give one dose adequate for the procedure, maintain blockade with careful monitoring, and allow spontaneous recovery. Repeat dosing is contraindicated. ### Why Sugammadex Is Not First-Line Here While sugammadex (a selective relaxant binding agent) can reverse rocuronium: - It is **not indicated for routine reversal of profound blockade** in the operating room when the patient is still anesthetized and surgery is complete - Sugammadex itself is renally cleared (90%), and its use in eGFR <30 is controversial and may require dose adjustment - Re-dosing rocuronium after sugammadex reversal in renal failure risks the same accumulation problem **Mnemonic:** **SAFE ROCURONIUM IN RENAL FAILURE = Single dose, Avoid repeat, Facilitate monitoring, Expect prolonged recovery** ### Train-of-Four Interpretation ```mermaid flowchart TD A[Train-of-Four Assessment]:::outcome --> B{Number of Twitches?}:::decision B -->|4/4 twitches| C[Adequate spontaneous recovery]:::action B -->|1-3/4 twitches| D[Partial blockade present]:::outcome B -->|0/4 twitches| E[Profound blockade]:::outcome D --> F{Renal failure?}:::decision E --> G{Renal failure?}:::decision F -->|Yes| H[Continue anesthesia, monitor, await recovery]:::action F -->|No| I[Consider reversal agent if needed]:::action G -->|Yes| J[Maintain blockade, NO repeat dosing]:::action G -->|No| K[Reversal or spontaneous recovery acceptable]:::action ``` [cite:Miller's Anesthesia 8e Ch 12; Stoelting's Pharmacology and Physiology in Anesthetic Practice 5e Ch 8]